p38α MAPK (mitogen-activated protein kinase) plays an important tumour suppressor role, which is mediated by both its negative effect on cell proliferation and its pro-apoptotic activity. Surprisingly, most tumour suppressor mechanisms co-ordinated by p38α have been reported to occur at the post-translational level. This contrasts with the important role of p38α in the regulation of transcription and the profound changes in gene expression that normally occur during tumorigenesis. We have analysed whole-genome expression profiles of Ras-transformed wild-type and p38α-deficient cells and have identified 202 genes that are potentially regulated by p38α in transformed cells. Expression analysis has confirmed the regulation of these genes by p38α in tumours, and functional validation has identified several of them as probable mediators of the tumour suppressor effect of p38α on Ras-induced transformation. Interestingly, approx. 10 % of the genes that are negatively regulated by p38α in transformed cells contribute to EGF (epidermal growth factor) receptor signalling. Our results suggest that inhibition of EGF receptor signalling by transcriptional targets of p38α is an important function of this signalling pathway in the context of tumour suppression.
INTRODUCTION
p38α MAPK (mitogen-activated protein kinase) is an ubiquitously expressed serine/threonine protein kinase, which is activated by many extracellular stimuli and co-ordinates numerous cellular processes [1, 2] . p38α can also negatively regulate malignant cell transformation, which seems to be accounted for by its inhibitory role on cell-cycle progression, and its stimulatory effect on apoptosis and differentiation [3, 4] .
Intriguingly, despite the recognized importance of p38α in the regulation of gene expression [5] [6] [7] [8] [9] , little is known about how this p38α function impinges on tumorigenesis. In fact, most of the known tumour suppressor mechanisms co-ordinated by p38α occur at the post-translational level. These include the posttranslational regulation of ERK1/2 (extracellular-signal-regulated kinase 1/2) pathway activity, protein stability of cyclin D1, subcellular localization/stability of Cdc25 (cell division cycle 25) phosphatases, EGFR [EGF (epidermal growth factor) receptor] intracellular fate, and up-regulation of cell-cycle inhibitors such as p21 Cip1 or p27 Kip1 [3, 4] . There are a few examples of the regulation of gene expression by p38α with potential relevance for malignant transformation, most notably the transcriptional control of cyclin D1 [10] or the cell-cycle inhibitor p16
INK4a [11] , and the upregulation of Egfr mRNA in lung tumours of p38α-deficient mice [12] .
We have investigated how transcriptional regulation contributes to the tumour suppressor effect of p38α by comparing wholegenome expression profiles of WT (wild-type) and p38α
− / − (p38α-deficient) MEFs (mouse embryonic fibroblasts) expressing oncogenic H-Ras G12V . Our previous work showed that p38α deficiency facilitates H-Ras G12V -induced transformation in these cells [13] [14] [15] . We have now identified a group of genes that are regulated by p38α in the context of malignant cell transformation, and have also functionally validated nine of these genes in anchorage-independent cell-growth assays. Interestingly, we have found that approx. 10 % of the genes whose expression is negatively regulated by p38α can potentially enhance EGFR signalling. These results provide further evidence for a key role of EGFR pathway down-regulation in tumour suppression by p38α.
MATERIALS AND METHODS

Microarray procedures and data analysis
mRNA was extracted from three biological replicates of exponentially proliferating WT and p38α − / − MEFs expressing H-Ras G12V using the Qiagen RNeasy kit according to the manufacturer's instructions. RNA quality was checked spectrophotometrically by its 260/280 nm absorbance ratio as well as by RT (reverse transcription)-PCR. RNAs were labelled with Cy5 (indodicarbocyanine) and Cy3 (indocarbocyanine), pooled, hybridized and processed with the Amersham Codelink 20K mouse platform (GeneCore Laboratory, EMBL, Heidelberg).
Microarray dataset normalization was performed via cyclic loess normalization. Differentially expressed genes were obtained by applying linear models with R limma package [16] (Bioconductor project, http://www.bioconductor.org) and multiple hypotheses testing was accounted for by adjusting the estimated significance level (P value) with the Benjamini and Hochberg FDR (false discovery rate) correction. Those genes with an FDR < 0.05 and a fold change >1.5 (accounting for a total of 2100 genes) were selected as differentially expressed between Abbreviations used: Cdc, cell division cycle; EGFR, EGF (epidermal growth factor) receptor; ERK, extracellular-signal-regulated kinase; FDR, false discovery rate; GEO, Gene Expression Omnibus; GSEA, gene set enrichment analysis; HEK, human embryonic kidney; MAPK, mitogen-activated protein kinase; MEF, mouse embryonic fibroblast; OHT, 4-hydroxytamoxifen; qRT-PCR, quantitative real-time PCR; ROS, reactive oxygen species; RT, reverse transcription; WT, wild-type. 1 To whom correspondence should be addressed (email angel.nebreda@irbbarcelona.org). Matrix breakdown [34] ; pro-invasive, proliferative and anti-apoptotic activities [35, 36] Enhanced in WT Enhanced in WT Cd9 (NM_007657) +5.19 CD9 antigen/motility-related protein (Mrp)-1
Proliferation and tumour development through EGFR activation [37, 38] Enhanced in WT Enhanced in WT Pmp22 (NM_008885) +4. 60 Peripheral myelin protein/growth arrest-specific (Gas)-3
Anti-proliferative and pro-apoptotic activity [39, 40] Reduced in p38α H-Ras G12V -expressing p38α − / − and WT MEFs and subsequently discriminated with a parametric one-way ANOVA test (P < 0.01) with the GeneSpring 6.2 software (Silicon Genetics). This latter analysis allowed us to cut down the number of differentially expressed genes to a more workable set of 202 genes, which corresponded to those genes deregulated + − 1.5-fold between H-Ras G12V -expressing p38α − / − and WT MEFs within the 99 % confidence level (P < 0.01) and an FDR < 0.05.
Gene functions were manually annotated on the basis of exhaustive searches in PubMed and Gene Ontology-based applications such as the FatiGO and Source Batch databases. The microarray data have been deposited in the GEO (Gene Expression Omnibus) database under accession number GSE26762.
GSEA (gene set enrichment analysis)
GSEA was performed with the EGFR-associated set of 19 genes identified in the present study compared with microarray data from [17] as a reference. Affymetrix arrays (GEO ID GSE9599) were normalized using RMA (Robust Multi-Array Average). Whole microarray genes were ranked based on limma moderated t statistic. After Kolmogorov-Smirnoff testing, the gene set was considered statistically significant if the FDR < 0.25, a widely accepted cut-off for the identification of biologically relevant gene sets [18] .
mRNA isolation and RT-PCR analysis
Total RNA was extracted from MEFs or mouse tumours [12, 14] using the RNeasy Kit (Qiagen) according to the manufacturer's instructions. The RNA concentration was determined by measuring the absorbance at 260 nm and the quality was monitored by the ratio of absorbance at 260/280 nm and by 1 % agarose gel electrophoresis. cDNA was prepared using MMLV (Moloney murine leukaemia virus) reverse transcriptase (Invitrogen) and used as the template for PCR amplification. PCR primers were designed with the Vector NTI 8 software (InforMax) and used at a final concentration of 160 nM (Supplementary Table S1 at http://www.BiochemJ.org/bj/434/ bj4340549add.htm). RT-PCR conditions were as follows: RT at 37
• C for 90 min, denaturation at 95 • C for 2 min, followed by 30-35 cycles of denaturation at 95
• C for 45 s, annealing at 55
• C for 45 s and elongation at 72
• C for 60 s. A final step of elongation at 72
• C for 10 min was performed. The products of the RT-PCR were analysed by 1 % agarose gel electrophoresis, stained with ethidium bromide and imaged using the Gel Doc 2000 system (Bio-Rad).
qRT-PCR (quantitative real-time PCR) analysis was performed as described previously [15] . Primer sequences are listed in Supplementary Table S2 at http://www.BiochemJ.org/bj/434/ bj4340549add.htm.
Cell culture and reagents
Primary WT and p38α
− / − MEFs were immortalized using the 3T3 protocol, maintained as described previously [14] and used as the starting biological material in the experiments described in the present study. The term MEFs is used throughout the present paper to refer to spontaneously immortalized cells or derivatives of them (i.e. H-Ras G12V transformed). MEFs expressing OHT (4-hydroxytamoxifen)-inducible H-Ras G12V have been described previously [14] . HEK (human embryonic kidney)-293 human epithelial cells were maintained in the same medium as MEFs and used for transient transfection. HEK-293T [HEK-293 cells expressing the large T-antigen of SV40 (simian virus 40)] cells were used to generate retroviruses to stably infect MEFs and were provided by Dr M. Serrano (CNIO, Madrid, Spain). transduction as described previously [14] . Cloning details, cDNA origin, amplification primers and restriction sites are provided in Supplementary Table S3 (at http://www.BiochemJ.org/bj/434/ bj4340549add.htm). Myc-tagged versions of pWZL-hygroGstm2 and pWZL-hygro-Cd9 were prepared by site-directed mutagenesis on the non-tagged constructs (QuikChange ® , Stratagene) and verified by sequencing. The retroviral construct MSCV-hygro-p38α [19] was used to re-express p38α in p38α
MEFs for the rescue experiments.
Immunoprecipitation
Control and H-Ras G12V -expressing WT MEFs were transduced with Cd9 or an empty vector, and then EGFR was immunoprecipitated. Subconfluent 10-cm cell-culture plates were washed twice with ice-cold PBS, scraped on ice and harvested by centrifugation at 400 g and 4
• C for 10 min. The cell pellets were lysed in 100-600 μl of modified RIPA lysis buffer [50 mM Hepes (pH 7.4), 150 mM NaCl, 10 % glycerol, 1.5 mM MgCl 2 , 1 mM EGTA, 1 % Triton X-100, 1 % sodium deoxycholate, 0.1 % SDS, 20 mM NaF, 0.1 mM sodium orthovanadate, 1 mM PMSF, 2.5 mM benzamidine, 2 μM microcystin and 10 μg/ml leupeptin and aprotinin]. Whole-cell extracts (500 μg) were immunoprecipitated with an anti-EGFR antibody (Santa Cruz Biotechnology) overnight at 4
• C. Immunoprecipitates were incubated with Protein G-Sepharose (Amersham) for 1 h at 4
• C, washed three times, analysed by SDS/PAGE and visualized with an anti-EGFR antibody (Santa Cruz Biotechnology).
Immunoblotting, transformation and tumorigenicity assays
Immunoblot analysis was performed as described previously [14] Cell proliferation {MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide]} and anchorage-independent growth (soft agar) assays were performed as described previously [14] . Briefly, soft agar assays were performed in duplicate with a top layer of 0.35 % agar and a bottom layer of 0.5 % agar. Cell colonies were stained with 0.1 % Crystal Violet (Sigma) at the end of the experiment and counted if bigger than 0.2 mm. Colony numbers normally displayed an S.D. of + − 500 colonies. Pictures of representative fields were taken at 40× magnification with a Leica MZ6 microscope coupled to an RS Photometrics camera.
Statistical analysis
Unless otherwise indicated, all results are expressed as means + − S.D. for at least three independent experiments. Statistical analysis was performed using a Student's t test with a statistically significant P value (P < 0.01). 
RESULTS
Gene expression profiling of H-
Gene expression validation by semi-quantitative RT-PCR in cultured MEFs
To validate microarray gene expression differences, 31 out of the 202 genes potentially regulated by p38α were selected for semi-quantitative RT-PCR analysis, which was performed on new mRNA preparations extracted from the two transformed MEF lines growing exponentially. Gene selection was based on the different mRNA expression levels in H-Ras G12V -p38α
compared with H-Ras G12V -WT MEFs, as well as on the putative involvement of each gene in Ras-induced transformation or p38α signalling. Out of the 31 genes selected, 19 were up-regulated and the other 12 were down-regulated in H-Ras G12V -p38α Table S6 at http://www.BiochemJ.org/bj/ 434/bj4340549add.htm). Two independent cellular systems were used to dissect the relative contribution of p38α and H-Ras G12V to the expression of these genes. The first involved established WT and p38α
MEFs constitutively expressing H-Ras G12V for at least 2 weeks [13, 14] , which allowed us to evaluate the steady-state gene expression levels in each cell line. The second consisted of WT and p38α − / − MEFs expressing an OHT-inducible form of HRas G12V (ER-HRas G12V ) [14] . This system allowed us to monitor gene expression in both cell lines in the absence of H-Ras G12V signalling as well as early (24 h) after its activation with OHT ( Figure 2A ).
We found that the majority of the genes analysed by semiquantitative RT-PCR were deregulated between stable H-Ras G12V -expressing WT and p38α
− / − MEFs ( Figures 2B and 2C , two right-hand lanes) in a way that mirrored the microarray results in more than 90 % of the cases (note the microarray foldchange column to the right-hand side). However, the differential expression levels of Ralgds, Rtn4 and Ctsl in H-Ras G12V -WT compared with H-Ras G12V -p38α − / − MEFs were less clear than expected from the microarray results. This might be related to sensitivity limitations of the semi-quantitative RT-PCR technique, at least for Rtn4 (+2.2) and Ctsl (+2.4), since their moderate up-regulation was detectable by qRT-PCR (Figures 3  and 4A ). Of note, we could not detect expression of Stac2, Rom1, Dpep1, Traf1 and Lzts2.
Concerning the remaining 26 genes, analysis of ER-HRas G12V -expressing WT and p38α
− / − MEFs revealed that the expression of half of them was dependent on p38α ( Figure 2B , first and third lanes marked with asterisks), whereas the other half were additionally influenced by H-Ras G12V signalling ( Figure 2C , second and fourth lanes marked with asterisks). Interestingly, the effect of H-Ras G12V on gene expression in the latter case was already clear 24 h after the onset of H-Ras G12V signalling and was usually maintained during the transformation process in MEFs stably expressing H-Ras G12V . However, the relative mRNA abundance of some genes in H-Ras G12V -expressing WT compared with p38α − / − MEFs was attenuated (Ralgds, Ctsl) or enhanced (Cd9, Ctsh) with time, arguing for a kinetic component in the regulation of gene expression by p38α and H-Ras G12V . This could in principle be due either to specific changes in p38α or H-Ras G12V signalling or to non-specific alterations or selective pressure related to the transformed phenotype. For example Cxcl1, Nck2 and Tnfrsf23 showed opposite expression patterns in early transformed compared with established cell lines, whereas Rtn4 and Snfl1k showed opposite regulation in non-transformed compared with H-Ras G12V -expressing cells. Interestingly, p38α reconstitution into p38α
MEFs rescued the expression levels of putative p38α-regulated genes to approximately WT levels in both non-transformed ( Figure 2D ) and transformed cells (Supplementary Figure S2 at http://www.BiochemJ.org/bj/434/bj4340549add.htm). Taken together, the results suggest that at least the selected genes that were analysed are indeed regulated by p38α, although some of them can be additionally modulated by the cellular context (e.g. non-transformed compared with transformed cells, and early compared with late transformation stages).
Gene expression validation by qRT-PCR in cultured cells and mouse tumours
In order to evaluate the relevance of the observed gene expression differences between WT and p38α − / − MEFs for in vivo tumorigenesis, selected genes were further analysed by qRT-PCR in subcutaneous tumours obtained from the injection of H-Ras G12V -expressing WT and p38α − / − MEFs in nude mice [14] , as well as in lung tumours induced by K-Ras G12V expression in WT and p38α
− / − mice [12] . We found that all of the genes analysed were similarly deregulated in a p38α-dependent manner in transformed MEFs, MEF-derived subcutaneous tumours Table S7 at http://www.BiochemJ.org/bj/434/bj4340549add.htm). These results link the p38α-mediated modulation of particular mRNAs with the ability of p38α to regulate tumorigenesis.
Functional validation of genes deregulated between H-Ras
G12V -transformed WT and p38α − / − MEFs Next, we selected nine out of the 26 genes mentioned above, according to their level of deregulation in H-Ras G12V -expressing 
p38α
− / − MEFs and their putative connection with the process of cell transformation, to perform functional studies (Table 1) . Three genes encoded membrane (Aig1) or extracellular matrix (Mmp3, Ctsh) proteins and were selected due to their acute deregulation in H-Ras G12V -expressing p38α − / − compared with WT MEFs. Little is known about Aig1 in the context of malignant transformation. In contrast, Mmp3 and Ctsh are known to be involved in tumour progression (Table 1) . Four other genes encoded the tyrosine-kinase-signal-modulating proteins CD9 and Nck2, the proliferation-regulating protein Pmp22 and the pleiotropic protein Rtn4, and were all up-regulated in the more transformed H-Ras G12V -p38α − / − MEFs, suggesting that enhanced expression of these genes might contribute to transformation. Accordingly, some of them have been described to be up-regulated in tumours and potentially associated with tumour progression (Table 1) . Finally, two genes that were down-regulated in H-Ras G12V -p38α − / − MEFs, namely Gstm2 and Egln3, were also considered good candidates to test functionally due to their reported roles in oxidative stress and apoptosis respectively (Table 1) .
We have previously reported that the absence of p38α enhances H-Ras G12V -induced anchorage-independent growth [14] . Thus genes found to be up-regulated in H-Ras G12V -p38α − / − MEFs were overexpressed in H-Ras G12V -WT MEFs (Table 1) to test whether they could enhance the ability of transformed cells to grow in soft agar. Proliferation rates were also measured in parallel, and overexpression was confirmed by immunoblotting or RT-PCR (Supplementary Figure S3A at http://www.BiochemJ.org/ bj/434/bj4340549add.htm), depending on the availability of antibodies. Interestingly, Mmp3, Cd9 and Rtn4 enhanced the ability of H-Ras G12V -WT MEFs both to proliferate and to grow anchorageindependently (Table 1 and Supplementary Figures S3B, S3C and S4 at http://www.BiochemJ.org/bj/434/bj4340549add.htm). Similarly, Nck2 stimulated the proliferation of H-Ras G12V -WT MEFs to p38α − / − levels, although it did not affect H-Ras G12V -induced soft agar growth (Table 1 and Supplementary Figures  S3B and S4) . These results suggest that p38α might regulate different traits of the cancer cell (i.e. proliferation and anchorageindependent growth) by specifically targeting the expression of distinct genes in each case. Overall, it appears that the down-regulation of these four genes by p38α may contribute to its inhibitory effect on H-Ras G12V -induced transformation of MEFs. In contrast, no conclusions could be drawn for Aig1 since we did not manage to express this gene (results not shown), whereas Pmp22 unexpectedly decreased, rather than enhanced, the transformed phenotype of H-Ras G12V -WT MEFs (Supplementary Figures S3D and S4 ). This would agree with the pro-apoptotic and anti-proliferative functions ascribed to Pmp22 (Table 1) , but raises the question of whether endogenous Pmp22 is actually functional in p38α
− / − MEFs, since Pmp22 overexpression in these cells (where it is already up-regulated) attenuates their transformed phenotype as well (Supplementary Figure S3D) .
In a complementary set of experiments, we overexpressed in H-Ras G12V -p38α − / − MEFs three genes found to be up-regulated in H-Ras G12V -WT cells (Table 1 ) and tested whether they could inhibit transformation. We found that Egln3 attenuated the proliferation rate and the ability to grow in soft agar of H-Ras G12V -p38α
MEFs to approximately H-Ras G12V -WT levels (Supplementary Figures S5A, S5B and 5C at http://www.BiochemJ.org/bj/434/ bj4340549add.htm), in agreement with its lower expression levels in p38α
− / − MEFs (Supplementary Table S6 at http:// www.BiochemJ.org/bj/434/bj4340549add.htm) and its reported pro-apoptotic activity (Table 1 ). In contrast, Ctsh affected neither proliferation nor soft agar colony formation in H-Ras G12V -p38α − / − MEFs (Table 1 and Supplementary Figures S5A and  S5B ). This is in agreement with the putative matrix remodelling function of Ctsh, which is likely to regulate tumour cell invasion rather than cell proliferation or anchorage-independent growth. Of note, Gstm2 did not significantly affect H-Ras G12V -p38α
MEFs, but enhanced the proliferation (Supplementary Figure  S5D) and soft agar growth [14] of H-Ras G12V -WT MEFs. This apparent paradox could be explained if one considers that Gstm2 overexpression interferes with the activation and subsequent proapoptotic function of p38α in H-Ras G12V -expressing cells [14] . Mechanistically, this involves Gstm2 binding to ASK1 (apoptosis signal-regulating kinase 1), an upstream activator of p38α, which in turn blocks the activation of the pathway by H-Ras G12V -induced ROS (reactive oxygen species). Thus cells overexpressing HRas G12V and Gstm2 bypass the inhibitory apoptotic response mediated by p38α, allowing the accumulation of high levels of ROS, which enhances malignant transformation. Since Gstm2 overexpression targets p38α activation, it is not surprising that it has no effect on H-Ras G12V -p38α − / − MEFs.
Regulation of EGFR signalling by transcriptional targets of p38α in malignant transformation
Experiments using mouse models of cancer suggest that EGFR transcription could be targeted by p38α for tumorigenesis regulation in vivo [12] , in agreement with studies using cultured cells [20] [21] [22] . Moreover, EGFR activity is enhanced in p38α-deficient MEFs and contributes to the more transformed phenotype of H-Ras G12V -p38α − / − MEFs [15] . We found a set of 19 genes that were deregulated between H-Ras G12V -expressing WT and p38α
− / − MEFs and were linked to EGFR signalling ( Table 2) . Most of these genes encode proteins that positively regulate EGFR signalling and were up-regulated in H-Ras G12V -p38α − / − MEFs, indicating negative regulation by p38α. These include the plasma membrane protein CD9 that stimulates EGFR activity by facilitating the interaction of the receptor with its ligands, the mitogenic EGFR ligand Areg previously associated with malignant cell transformation, the transcription factor Klf5 that stimulates EGFR expression, the Src-family kinase Hck that participates in EGFR recycling and signal relay as well as in cell survival, and the tyrosine kinase substrate Eps8 that amplifies EGFR signalling following mitogenic stimulation (Table 2) . Validation by qRT-PCR confirmed the differential expression of these genes in H-Ras G12V -p38α − / − compared with H-Ras G12V -WT MEFs (Figure 4A ), as predicted from the microarray results.
To strengthen the implication of the 19 gene dataset in the regulation of EGFR signalling, we performed GSEA. We found that our set of p38α-regulated genes aligned with the EGFR-associated gene signature (GEO ID GSE9599) of a study correlating the sensitivity of human pancreatic tumour cell lines to the EGFR inhibitor erlotinib with the expression of an EGFRassociated gene network that sustains high levels of EGFR activity [17] . Interestingly, GSEA revealed that our 19 gene cluster was significantly enriched in erlotinib-sensitive pancreatic tumours (FDR q value = 0.165) (Supplementary Figure S6 at http://www.BiochemJ.org/bj434/bj4340549add.htm) correlating with high EGFR activity. This result supports the importance of EGFR signalling inhibition by p38α in the regulation of cell transformation.
At the mechanistic level, we confirmed that Cd9 overexpression in H-Ras G12V -WT MEFs not only enhanced their transformed phenotype to H-Ras G12V -p38α − / − levels (Supplementary Figures  S3B and S3C ), but also activated EGFR kinase activity, as indicated by higher levels of phospho-EGFR Y1068 ( Figure 4B , left-hand panel) and its downstream signalling pathways ERK1/2 and Akt ( Figure 4B , right-hand panel). This argues that p38α negatively regulates cell transformation, at least in part, by inhibiting EGFR via down-regulation of several genes that stimulate its activity or downstream signal relay. Of note, the interplay between EGFR and p38α in cell transformation might not be limited to a cluster of EGFR-regulating genes, but also involve direct regulation of the Egfr mRNA by p38α. We found that Egfr mRNA was up-regulated in the absence of p38α in three different cellular systems: H-Ras G12V -transformed MEFs growing exponentially, subcutaneous xenografts derived from H-Ras G12V -expressing MEFs and K-Ras V12 -induced lung tumours in mice ( Figure 4C ).
DISCUSSION
Cancer is a genetic disease characterized by the simultaneous disruption of several cellular traits required for organism homoeostasis. At the molecular level, the combination of deregulated cell proliferation and reduced apoptosis is thought to set the foundations for neoplastic progression. Accordingly, the ability of p38α to engage cell-cycle arrest and apoptosis has been shown to play an important tumour suppressor role [3, 4] . p38α counteracts the transforming activity of oncogenic Ras in several cellular and animal models through various mechanisms, with most of them occurring at the post-translational level [11, 12, 14, 23] . However, cancer progression is normally accompanied by profound alterations in gene expression, which prompted us to investigate transcriptional targets of p38α in the regulation of tumorigenesis. We have found a number of genes not previously connected to p38α signalling that are likely to mediate its negative effect on H-Ras G12V -induced transformation. Intriguingly, our analysis has also identified various p38α-induced genes that are related to cell migration, invasion and angiogenesis, which may belong to a family of p38α effectors mediating some of its less characterized pro-oncogenic functions [24] . In fact, emerging evidence suggest that p38α may have oncogenic rather than tumour suppressive functions in some advanced human tumours [4] . Further studies are needed to understand the cellular contexts in which p38α can either suppress or promote tumour formation. In the present paper we report a set of p38α-regulated genes that are associated with tumour suppressor functions of p38α in different tumour models, and may be useful to identify human cancers where p38α negatively regulates tumour formation.
New p38α effectors in the regulation of cell survival and proliferation
Down-regulation of p38α enhances H-Ras
G12V -induced transformation of MEFs, as indicated by their increased proliferation and survival, refringent morphology, loss-of-contact inhibition and anchorage-independent growth [14] . Not surprisingly, we have found that genes stimulating cell proliferation and survival are negatively regulated by p38α, including Ralgds, a Ras effector that promotes cell survival [25] , and Tnfrsf23, a putative TNF (tumour necrosis factor) receptor decoy that inhibits apoptosis [26] . Conversely, apoptosis-stimulating genes such as Egln3 [27] are up-regulated in the less-transformed H-Ras G12V -WT MEFs, in line with the importance of the apoptotic activity of p38α for tumour suppression [14] . Of note, p38α seems to regulate Egln3 expression at both transcriptional and post-translational levels [28] . It is possible that other genes found in the present study are also post-transcriptionally regulated by p38α, for instance through the well-known p38α-MK2 (MAPK-activated protein kinase 2)-mediated stabilization of mRNAs containing AU-rich 3 -UTRs (untranslated regions) [29] .
Potential membrane targets of p38α in cell transformation
Apart from survival and proliferation, p38α can also regulate other traits of the cancer cell, such as cell morphology, contact inhibition and anchorage-independent growth, which are likely to be regulated by signals relayed from plasma membrane proteins [14, 15] . Previous attempts to identify proteins that were differentially expressed in the membranes of H-Ras G12V -expressing WT and p38α − / − MEFs had limited success [13] . Interestingly, we now report several p38α-regulated genes encoding integral-to-membrane or membrane-associated proteins that may be involved in such processes (Supplementary Table  S5 ). These include Ezr, encoding the cytoskeleton protein ezrin known to be important for the regulation of cell-cell contact inhibition and tumorigenesis [30] , as well as various genes encoding transmembrane proteins, such as Tspan13 (tetraspanin 13), or Pcdh7 and Pcdh10 (protocadherins). Of note, certain protocadherins (i.e. Fat1) are emerging as important regulators of contact inhibition [31] , a process where p38α plays a key role [15] . Future studies should reveal whether these proteins may link p38α signalling with the regulation of membrane-mediated cellular processes associated with malignant transformation.
The EGFR pathway as a transcriptional target of p38α in cell transformation
A striking finding of the present study has been the identification of 19 genes ( Table 2 ) that impinge on EGFR signalling and whose expression seems to be co-ordinately regulated by p38α to inhibit malignant transformation. These include genes encoding proteins that enhance EGFR expression (Klf5), activation (Hck, Cd9, Prkca, Areg) and downstream signalling (Nck2, Limk2, Mmp3) or that regulate EGFR intracellular trafficking (Ctsl, Lamp2, Arfgap3, Cdc42ep5). Interestingly, we have shown that Cd9 overexpression not only stimulates EGFR signalling in HRas G12V -WT cells, but also enhances transformation to H-Ras G12V -p38α − / − levels. The ability of p38α to down-regulate EGFR signalling at various levels may also contribute to the inhibitory role of p38α in Ras-induced transformation, since Ras has been shown to require EGFR signalling for full transformation [32, 33] .
We have recently reported that p38α can inhibit EGFR at the post-translational level upon cell-cell contact [15] , preventing cell overgrowth at high cellular densities. The relative contribution of transcriptional compared with post-translational regulation to the overall effect of p38α on EGFR signalling is unclear and may depend on the transformed state of the cell, the cell-cycle phase and the scope of the response induced by p38α. For instance, p38α regulates Egfr mRNA levels in proliferating H-Ras G12V -transformed cells, but no differences were found in Egfr mRNA abundance between contact-inhibited, non-transformed WT and p38α
− / − MEFs [15] . It is possible that the post-translational regulation of EGFR by p38α in contact inhibition is aimed at eliciting a fast response, whereas the long-term inhibition of H-Ras G12V transformation by p38α requires tuning the steadystate expression levels of genes encoding proteins, which in turn impinge on EGFR signalling.
In summary, we have identified and validated in different models of tumorigenesis several p38α targets that are functionally implicated in transformation. A significant number of the genes that are down-regulated by p38α at the mRNA level encode positive regulators of EGFR signalling, suggesting that inhibition of this pathway probably represents an important tumour suppressor function of p38α. Table 2 of the main text with the EGFR-associated gene network in dataset GSE9599. NM_025446  GCTCCATCCTGTGCAACTAC  TTTAGTACTTCTCCAAGCAGG  Loxl1  NM_010729  GCCTTGACCGTCGTTACTCG  GCTTCGCACGGGCAAGTAAG  Mmp3  NM_010809  TACTGAAGGTGGTACAGAGC  GCATAGGCATGAGCCAAGAC  Nr4a1  NM_010444  ATCCTCCAGCGGCTCTGAG  TTTAGATCGGTATGCCAGGC  Ctsh  NM_007801  AGATTCAAGCCCACAACCAG  ATGATGTCACGTGGGTGGG  Egln3  NM_028133  TCAGACACTCTCTTTGCCAG  CGAGGGTGGCTAACTTTCG  Plcg2  NM_172285  CCACTACTGTGCCATTGCTG  TCCATAGTAGACCGGATCCG  Ramp3  NM_019511  CTGCAACGAGACAGGGATGC  GAACCGCGATCAGTGGGATG  Pde8a  NM_008803  CAAATTCATGACTTGTGTGTGC  GAGGCAGGCTTTTAGAAATTC  Sardh  NM_138665  GCTCCTCTGGCATGTATGC  TGATATGGATCCAATCGGGG  Rab3b  NM_023537  TGGGTTTGACTTCTTTGAAGC  AATGGAGAGAAGCGGAGGAG  Ralgds  NM_009058  AATGCCATCTCCTCCATCCTG  ATGTCACCACTTGGCTGGGC  Cd9  NM_007657  CTGCTCTTCGGATTTAACTTC  TCTTCAATATAACTTACAACCTG  Pmp22  NM_008885  TTTAGCAGAAGTATCCACTGC  CATCTTAGTCCACACAGTTGG  Dpep  NM_007876  AGACATCCTACAGGCTTTCC  AGACATCCTACAGGCTTTCC  Ctsl  NM_009984  AACGCCTTCGGTGACATGAC  TCCAGACTCAGAATTAAGCAC  Nck2  NM_010879  GGCACTGCACTGAGCAATG  GGACACAGCTCTCGGAGTG  Gstm2  NM_008183  CACCAGCACTATGCTTATGAC  ACTTTATTGAGAACCAAATGGG  Brca2  NM_009765  ACTCCTGGGCTTCTGCCAC  GCCCTTGTGTGTGGCTGAG  Rtn4  NM_024226  TATTGCCAGAGGACACCTGC  GCCCCAACTGATCAAACAAAC  Krt1-19  NM_008471  CAGATTGACAATGCTCGCCTG  TCGACACCGGGAGTGGAATC  Tnfrsf23  NM_024290  TTCAGCCACGTCTCCAGTC  TGAAAGAGTTGCCTCCATGG  Cxcl1  NM_008176  GGATTCACCTCAAGAACATCC  AAATAAAAACCACACACTTTGTG  Foxd1  NM_008242  GAAGTTCCCCGCCTTGGCAG  CTCTCGATGGAGAAGGGCG  Arhgdib  NM_007486  CCAACAGTTCCCAACGTGAC  ACTCTGAGATGGGGTAAG  Dock8  NM_028785  GAGACGGTTAATGAAGTCTAC  CTCTTCTGACTGTCAACTCTG  Snf1lk  NM_010831  GCTAGCAGATTTTGGATTTGG  GCAGAGGAGGAGACAATTATG Table S2 qRT-PCR primers used for microarray gene expression validation NM_025446  GCTCCATCCTGTGCAACTAC  TTTAGTACTTCTCCAAGCAGG  Rab3b  NM_023537  TGGGTTTGACTTCTTTGAAGC  AATGGAGAGAAGCGGAGGAG  Loxl1  NM_010729  GCCTTGACCGTCGTTACTCG  GCTTCGCACGGGCAAGTAAG  Mmp3  NM_010809  TACTGAAGGTGGTACAGAGC  GCATAGGCATGAGCCAAGAC  Ralgds  NM_009058  AATGCCATCTCCTCCATCCTG  ATGTCACCACTTGGCTGGGC  Cd9  NM_007657  GATTCGACTCTCAGACCAAG  ATCCTTGCTCCGTAACTTTTG  Tnfrsf23  NM_024290  TTCAGCCACGTCTCCAGTC  TGAAAGAGTTGCCTCCATGG  Nck2  NM_010879  GGCACTGCACTGAGCAATG  GGACACAGCTCTCGGAGTG  Rtn4  NM_024226  GAAGACTGGAGTGGTGTTTG  GCTGTTCACATGACCAAGAG  Gstm2  NM_008183  ATGGGGGACGCTCCTGACT Other: Stc1, Kcnk3, Cln3, Aqp5, Tmed8 Lipid homoeostasis (4 %) Fabp4, Abhd4, Crabp1, Sgms2, Ppap2b, Lrp10, Tpd52l1, Plekha3, Stx8 Unknown (10 %) Ccdc106, Stac2, Ccdc109b, Lrrc17, Magoh-rs1, BC029169, Sdpr, Cd68, 4933411B09Rik, Nudt18, C1galt1c1, Rnh1, Oit3, Mpp10, Ypel5, Fam115a, Clip3, Casd1, Lce3c, 1110012L19Rik, Dleu2, Sh3d19, 1810030N24Rik, 2210417D09Rik, Hddc3, Phyhip *According to annotations in Gene Ontology, FatiGO, Source Batch and PubMed.
Table S6 Genes selected for semi-quantitative RT-PCR validation
Only genes with FDR < 0.05, P < 0.01 and fold-change > 1.5 or < − 1.5 are included. 
